Cargando…
Long-term surviving cancer patients as a source of therapeutic TCR
We have established a platform for the isolation of tumour-specific TCR from T cells of patients who experienced clinical benefit from cancer vaccination. In this review we will present the rationale behind this strategy and discuss the advantages of working with “natural” wild type TCRs. Indeed, th...
Autores principales: | Inderberg, Else Marit, Wälchli, Sébastien |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183495/ https://www.ncbi.nlm.nih.gov/pubmed/31915853 http://dx.doi.org/10.1007/s00262-019-02468-9 |
Ejemplares similares
-
Sympathetic improvement of cancer vaccine efficacy
por: Inderberg, Else Marit, et al.
Publicado: (2020) -
Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
por: Mensali, Nadia, et al.
Publicado: (2019) -
Exercise and cancer: from “healthy” to “therapeutic”?
por: Idorn, Manja, et al.
Publicado: (2017) -
Correction to: Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
por: Mensali, Nadia, et al.
Publicado: (2019) -
A TCR-based Chimeric Antigen Receptor
por: Walseng, Even, et al.
Publicado: (2017)